When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Become Profitable?
When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Become Profitable?
We feel now is a pretty good time to analyse Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) business as it appears the company may be on the cusp of a considerable accomplishment. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. With the latest financial year loss of US$140m and a trailing-twelve-month loss of US$111m, the US$7.3b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Intra-Cellular Therapies' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company.
我們認爲現在是分析Intra-Cellular Therapies, Inc.(納斯達克: ITCI )業務的好時機,因爲該公司似乎即將取得重大成就。Intra-Cellular Therapies, Inc.是一家生物製藥公司,專注於在美國通過針對中樞神經系統(CNS)中的細胞內信號傳導機制,發現、臨床開發和商業化小分子藥物,以滿足主要的神經精神和神經系統疾病的治療需求。在最新的財年中,這家市值73億美元的公司損失了1.4億美元,而在過去十二個月中,虧損達到了1.11億美元,公司將距其盈虧平衡目標更近。最緊迫的問題是Intra-Cellular Therapies實現盈利的路徑,它將何時盈虧平衡?以下是行業分析師對該公司預期的高級摘要。
According to the 15 industry analysts covering Intra-Cellular Therapies, the consensus is that breakeven is near. They expect the company to post a final loss in 2024, before turning a profit of US$116m in 2025. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 60% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
根據對Intra-Cellular Therapies的15名行業分析師的調查,共識是該公司已經接近盈虧平衡點。他們預計該公司將在2024年發佈最終的虧損報告,然後在2025年實現1.16億美元的利潤,因此該公司預計在一年多的時間內實現盈虧平衡點。爲了達到這個盈虧平衡點,我們計算了公司必須年均增長的速度。它得出的結果是預計平均年增長率爲60%,這是相當樂觀的!如果企業增長速度緩慢,將比預期的時間更晚實現盈利。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240707/0-36bbcc30291c0e9459c870550a530c91-0-867d35286072bce7b6e8ae45ea852acb.png/big)
Given this is a high-level overview, we won't go into details of Intra-Cellular Therapies' upcoming projects, however, take into account that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
由於這是一個高層次的概述,我們不會詳細介紹Intra-Cellular Therapies即將推出的項目。但需要考慮到,一家制藥公司通常擁有波動的現金流,這取決於該企業所處的藥品和產品開發階段。這意味着公司即將迎來大量增長並不是不正常的,因爲公司正在開始收穫早期投資的好處。
One thing we'd like to point out is that Intra-Cellular Therapies has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
我們想指出一件事:Intra-Cellular Therapies的資產負債表上沒有任何債務,這對於一個消耗現金的製藥公司來說是相當不尋常的,因爲這類公司通常相對於股本擁有很高的債務。該公司目前完全依靠股東提供資金,沒有任何債務義務,這減少了還款方面的風險,使其成爲一個風險較小的投資。
Next Steps:
下一步:
There are too many aspects of Intra-Cellular Therapies to cover in one brief article, but the key fundamentals for the company can all be found in one place – Intra-Cellular Therapies' company page on Simply Wall St. We've also compiled a list of essential factors you should further research:
Intra-Cellular Therapies的方方面面不能在一篇簡短的文章中全部涵蓋,但是該公司的關鍵基本面可以在一個地方找到——Simply Wall St的Intra-Cellular Therapies公司頁面。我們還編制了一個必要性因素的列表供您進一步研究:
- Valuation: What is Intra-Cellular Therapies worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Intra-Cellular Therapies is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Intra-Cellular Therapies's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Intra-Cellular Therapies今天的價值是多少?未來的增長潛力是否已經被市場納入價格?我們的免費研究報告中的內在價值信息圖表可以幫助您直觀地了解Intra-Cellular Therapies是否被市場低估。
- 管理團隊:經驗豐富的管理團隊增強了我們對業務的信懇智能 - 看看誰坐在Intra-Cellular Therapies的董事會上和CEO的背景。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com